National Health and Moderna vaccine will now go into it’s final 30,000 person testing stage with excellent first results from limited testing…
There IS the first of several vaccines now available for those wanting to be the test subjects in the vaccines final testing stage…
An experimental vaccine to treat COVID-19 manufactured by Moderna was able to induce an immune response in all of the volunteers in an early-stage trial, according to data published online in a medical journal.
The initial results, published in The New England Journal of Medicine on Tuesday, showed the vaccine was generally safe and well tolerated in 45 volunteers, with no serious adverse events.
The study, run by the National Institutes of Health, showed that some antibodies were produced after one dose of the vaccine, but a second dose four weeks later was needed before the volunteers showed a dramatic immune response.
The results were “encouraging, and represent an important step forward in the clinical development of mRNA-1273, our vaccine candidate against COVID-19,” Moderna Chief Executive Officer Stéphane Bancel said in a statement.
There are still many unknowns about immunity, including whether antibodies actually protect against infection and just how much protection would be gained.
Moderna is expected to begin a much larger-scale study of the vaccine on July 27, a stage three trial that will enroll 30,000 participants across 87 locations. The company’s stage two trial began enrollment in late May.
The primary goal of stage three will be the prevention of symptomatic COVID-19. Moderna said key secondary endpoints will include prevention of severe COVID-19 (as defined by the need for hospitalization) and prevention of infection by the coronavirus….